Woo Sun Kwon

889 total citations
51 papers, 677 citations indexed

About

Woo Sun Kwon is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Woo Sun Kwon has authored 51 papers receiving a total of 677 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 21 papers in Pulmonary and Respiratory Medicine and 19 papers in Molecular Biology. Recurrent topics in Woo Sun Kwon's work include Cancer Genomics and Diagnostics (11 papers), Gastric Cancer Management and Outcomes (9 papers) and HER2/EGFR in Cancer Research (5 papers). Woo Sun Kwon is often cited by papers focused on Cancer Genomics and Diagnostics (11 papers), Gastric Cancer Management and Outcomes (9 papers) and HER2/EGFR in Cancer Research (5 papers). Woo Sun Kwon collaborates with scholars based in South Korea, United States and Austria. Woo Sun Kwon's co-authors include Sun Young Rha, Hyun Cheol Chung, Hei‐Cheul Jeung, Hyo Song Kim, Joong Bae Ahn, Tae Soo Kim, Choong‐kun Lee, Tae Soo Kim, Minkyu Jung and Jae Kyung Roh and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Woo Sun Kwon

48 papers receiving 672 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Woo Sun Kwon South Korea	16	401	271	267	128	89	51	677
Claudia Sandomenico Italy	18	562 1.4×	366 1.4×	404 1.5×	124 1.0×	95 1.1×	52	987
Marianna Silletta Italy	14	224 0.6×	214 0.8×	157 0.6×	87 0.7×	63 0.7×	42	613
Stefania Infusino Italy	11	365 0.9×	210 0.8×	179 0.7×	104 0.8×	109 1.2×	18	669
Muaiad Kittaneh United States	16	447 1.1×	312 1.2×	294 1.1×	149 1.2×	57 0.6×	40	739
Yingjie Huang United States	11	493 1.2×	404 1.5×	383 1.4×	53 0.4×	79 0.9×	26	832
M. Ebert Germany	11	328 0.8×	271 1.0×	240 0.9×	189 1.5×	108 1.2×	17	732
Ruixuan Geng China	12	254 0.6×	196 0.7×	234 0.9×	148 1.2×	58 0.7×	29	556
Akitaka Makiyama Japan	17	715 1.8×	412 1.5×	193 0.7×	74 0.6×	154 1.7×	116	994
Eileen Regan United States	16	620 1.5×	238 0.9×	200 0.7×	94 0.7×	164 1.8×	34	907
Motokazu Suyama Japan	12	487 1.2×	258 1.0×	433 1.6×	208 1.6×	119 1.3×	31	954

Countries citing papers authored by Woo Sun Kwon

Since Specialization

Citations

This map shows the geographic impact of Woo Sun Kwon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Woo Sun Kwon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Woo Sun Kwon more than expected).

Fields of papers citing papers by Woo Sun Kwon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Woo Sun Kwon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Woo Sun Kwon. The network helps show where Woo Sun Kwon may publish in the future.

Co-authorship network of co-authors of Woo Sun Kwon

This figure shows the co-authorship network connecting the top 25 collaborators of Woo Sun Kwon. A scholar is included among the top collaborators of Woo Sun Kwon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Woo Sun Kwon. Woo Sun Kwon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kim, Chang Gon, Harim Koo, Woo Sun Kwon, et al.. (2025). Use of integrated multi-omics profiling in renal cell carcinoma to identify molecular subtypes and associated clinical outcomes and therapeutic vulnerabilities.. Journal of Clinical Oncology. 43(5_suppl). 588–588. 1 indexed citations

Kwon, Woo Sun, et al.. (2024). Identifying Anti-cancer Effects and Exploring the Mechanism of an MPS1/TTK Inhibitor in Gastric Cancer. Cancer Research and Treatment. 57(3). 803–820. 1 indexed citations

Koo, Dong‐Hoe, Minkyu Jung, Yeul Hong Kim, et al.. (2024). Varlitinib and Paclitaxel for EGFR/HER2 Co-expressing Advanced Gastric Cancer: A Multicenter Phase Ib/II Study (K-MASTER-13). Cancer Research and Treatment. 56(4). 1136–1145. 3 indexed citations

Lee, Choong‐kun, Jii Bum Lee, Se Jin Park, et al.. (2023). Second-line chemoimmunotherapy with nivolumab and paclitaxel in immune-related biomarker-enriched advanced gastric cancer: a multicenter phase Ib/II study. Gastric Cancer. 27(1). 118–130. 10 indexed citations

Lee, Choong‐kun, Soon Sung Kwon, Woo Sun Kwon, et al.. (2023). Clinical relevance of clonal hematopoiesis and its interference in cell-free DNA profiling of patients with gastric cancer. Clinical Chemistry and Laboratory Medicine (CCLM). 62(1). 178–186. 5 indexed citations

Jung, Seung‐Hyun, Choong‐kun Lee, Woo Sun Kwon, et al.. (2023). Monitoring the Outcomes of Systemic Chemotherapy Including Immune Checkpoint Inhibitor for HER2-Positive Metastatic Gastric Cancer by Liquid Biopsy. Yonsei Medical Journal. 64(9). 531–531. 5 indexed citations

Lee, CK, et al.. (2023). 1551P Clinicopathologic characteristics and genomic profiling of HER2-low advanced gastric cancer. Annals of Oncology. 34. S869–S869. 4 indexed citations

Jung, Minkyu, Jii Bum Lee, Hyo Song Kim, et al.. (2023). First-in-Human Phase 1 Study of a B Cell– and Monocyte-Based Immunotherapeutic Vaccine against HER2-Positive Advanced Gastric Cancer. Cancer Research and Treatment. 56(1). 208–218. 10 indexed citations

Kang, Joon Hee, Hyeon Joo Kim, Eunji Im, et al.. (2023). Discovery of novel 1H-benzo[d]imidazole-4,7-dione based transglutaminase 2 inhibitors as p53 stabilizing anticancer agents in renal cell carcinoma. Bioorganic Chemistry. 143. 107061–107061.

10.

Lee, Choong‐kun, Hong Jae Chon, Woo Sun Kwon, et al.. (2022). The UGT1A9*22 genotype identifies a high-risk group for irinotecan toxicity among gastric cancer patients. Genomics & Informatics. 20(3). e29–e29. 1 indexed citations

11.

Seo, Jieun, Choong‐kun Lee, Saeam Shin, et al.. (2022). Analytical and Clinical Validation of Cell-Free Circulating Tumor DNA Assay for the Estimation of Tumor Mutational Burden. Clinical Chemistry. 68(12). 1519–1528. 17 indexed citations

12.

Lee, Choong‐kun, Sun Young Rha, Hyo Song Kim, et al.. (2022). A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer. Nature Communications. 13(1). 6002–6002. 33 indexed citations

13.

Bae, Hyun-Joo, Woo Sun Kwon, Tae Soo Kim, et al.. (2021). Inhibition of the bromodomain and extra-terminal family of epigenetic regulators as a promising therapeutic approach for gastric cancer. Cellular Oncology. 44(6). 1387–1403. 5 indexed citations

14.

Bae, Hyun-Joo, Woo Sun Kwon, Jingmin Che, et al.. (2020). Transcriptome analysis of iBET-151, a BET inhibitor alone and in combination with paclitaxel in gastric cancer cells. Genomics & Informatics. 18(4). e37–e37. 4 indexed citations

15.

Bae, Hyun-Joo, Woo Sun Kwon, Sejung Park, et al.. (2020). p16 methylation is a potential predictive marker for abemaciclib sensitivity in gastric cancer. Biochemical Pharmacology. 183. 114320–114320. 11 indexed citations

16.

Park, Hyung Soon, Woo Sun Kwon, Sejung Park, et al.. (2019). Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer. Journal for ImmunoTherapy of Cancer. 7(1). 268–268. 28 indexed citations

17.

Kim, Hyun Jeong, Woo Sun Kwon, Tae Soo Kim, et al.. (2018). Casein Kinase 2 Inhibitor, CX-4945, as a Potential Targeted Anticancer Agent in Gastric Cancer. Anticancer Research. 38(11). 6171–6180. 16 indexed citations

18.

Kwon, Woo Sun, Sun Young Rha, Hei‐Cheul Jeung, Tae Soo Kim, & Hyun Cheol Chung. (2017). Modulation of HAT activity by the BRCA2 N372H variation is a novel mechanism of paclitaxel resistance in breast cancer cell lines. Biochemical Pharmacology. 138. 163–173. 9 indexed citations

19.

Chang, Hang‐Seok, Sun Young Rha, Hei‐Cheul Jeung, et al.. (2008). Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. Annals of Oncology. 20(2). 272–277. 93 indexed citations

20.

Kwon, Woo Sun, Sun Young Rha, Yeon Ho Choi, et al.. (2006). Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines. Pharmacogenetics and Genomics. 16(6). 429–438. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact